No Data
No Data
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers Across 15 U.S. States
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development ...
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development...
H.C. Wainwright Maintains Co-diagnostics(CODX.US) With Hold Rating, Maintains Target Price $2
H.C. Wainwright analyst Yi Chen maintains $Co-diagnostics(CODX.US)$ with a hold rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success rate of 27.2% and a t
HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $2 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Co-Diagnostics (NASDAQ:CODX) with a Neutral and maintains $2 price target.
Warning! US experts are concerned that if the bird flu virus mutates and evolves, a pandemic may occur.
This round of bird flu transmission has the characteristic of wide spread and extremely strong infectivity. At present, apart from Australia, relevant cases have been reported in other continents around the world. In addition to livestock, there have been several cases of human infection with avian flu virus this year, which has greatly alarmed the academic community. Former director of the US Centers for Disease Control and Prevention warned that humans may face a pandemic of bird flu.
Express News | Co-Diagnostics, Inc. Submits First FDA 510(K) Application for Co-Dx Pcr Pro Platform